Docket Room.
SB 2561·MS·senate

Ibogaine; authorize MSDH to select a consortium to conduct a drug development clinical trial to secure FDA's approval of.

FailedFiled Jan 19, 2026
Sponsor: Harkins
Latest Action

(S) Died In Committee

Feb 3, 2026

Email me when SB 2561 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track SB 2561. By continuing you agree to the Terms and Privacy Policy.

Summary

The bill would let Mississippi’s Department of Health choose a partnership of a drug developer, a university and a hospital to conduct a clinical trial of ibogaine for opioid and other substance‑use disorders. The consortium would receive state funding only after matching non‑state money, file an IND with the FDA, and try to obtain breakthrough‑therapy status. The measure failed and never left the Senate committee.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about SB 2561

3 free questions a day, no account

History

  1. Died In Committee
  2. Referred To Public Health and Welfare

Sponsors

  • Harkins · sponsor

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when SB 2561 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track SB 2561 free

Or ask your AI assistant about SB 2561 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice